| Developers: | Binnopharm Group (BFG) |
| Date of the premiere of the system: | 2024/06/07 |
| Branches: | Pharmaceuticals, Medicine, Healthcare |
Main article: Allergy
2024: Launch of Dermastil ACOS antihistamine
The pharmaceutical company Binnopharm Group has launched the production of the antihistamine Dermastil AKOS gel for external use 0.1% in three volumes - 30 gr, 50 gr and 100 gr. The drug will expand the line of modern generics in the dermatological segment, which shows active growth. The company announced this on June 7, 2024.
Dermastil AKOS has already entered civilian circulation. The gel is manufactured at the Synthesis production site (part of Binnopharm Group). The drug has an antiallergic and antipruritic effect, and also has a pronounced local anesthetic effect. The drug is indicated for use in adults and children aged 1 month or more.
The company's portfolio includes more than ten drugs of various forms to combat allergies. Dermastil AKOS gel will expand the line of drugs for external use.
 | We always look at the market needs for certain drugs. The demand for antihistamines is stable, so the introduction of Dermastil ACOS gel on the market will contribute to meeting the needs of patients for a high-quality external drug. The market volume at the moment is 1.4 billion rubles, with an increase of 34% (MAT '3 2024). Binnopharm Group plans to take a high position in this segment, said Sergey Komarov, director of planning and business analysis at Binnopharm Group.
|  |
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |